Cost-utility analysis of valsartan, enalapril, and candesartan in patients with heart failure in Iran

ABSTRACT:

Background

Today, heart failure is one of the leading causes of death and disability in most developed and developing countries. By 2030, more than 23.3 million people are projected to die of cardiovascular diseases each year, and the prevalence of heart failure is expected to increase by 25%. One of the preventive interventions is pharmacological interventions which can be used to reduce the complications of cardiovascular diseases such as heart failure. One of the most important pharmacological interventions in patients with heart failure is the use of antihypertensive drugs such as candesartan, enalapril, and valsartan. This study aimed to compare the cost-utility of candesartan, enalapril, and valsartan in patients with heart failure using the Markov model in Iran in 2020.

SUBMITTER: Ravangard R 

PROVIDER: S-EPMC10476319 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature